Vetnostrum (6936) reported revenue of NT$134.8 million for Oct 2026, +13.8% year on year and +15.8% from the previous month. Revenue for Jan–Oct 2026 was NT$1.25 billion (+8.0% year on year).
In Oct 2026, it ranked No. 60 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$134.8 million | +13.8% | +15.8% |
| Sep 2026 | NT$116.4 million | -6.9% | +2.3% |
| Aug 2026 | NT$113.8 million | -6.2% | -21.8% |
| Jul 2026 | NT$145.6 million | +13.1% | +24.1% |
| Jun 2026 | NT$117.3 million | -0.4% | -7.0% |
| May 2026 | NT$126.1 million | +19.3% | -4.6% |
| Apr 2026 | NT$132.3 million | +27.2% | +0.0% |
| Mar 2026 | NT$132.3 million | +15.7% | +43.3% |
| Feb 2026 | NT$92.3 million | -11.7% | -35.8% |
| Jan 2026 | NT$143.8 million | +18.1% | +19.7% |
| Dec 2025 | NT$120.1 million | -3.8% | -10.4% |
| Nov 2025 | NT$134.1 million | +41.2% | +13.3% |
| Oct 2025 | NT$118.4 million | +12.0% | -5.3% |
| Sep 2025 | NT$125.1 million | +16.6% | +3.1% |
| Aug 2025 | NT$121.4 million | -9.6% | -5.7% |
| Jul 2025 | NT$128.7 million | +7.9% | +9.3% |
| Jun 2025 | NT$117.8 million | +9.2% | +11.4% |
| May 2025 | NT$105.8 million | -6.5% | +1.7% |
| Apr 2025 | NT$104 million | -2.7% | -9.1% |
| Mar 2025 | NT$114.3 million | +32.7% | +9.3% |
| Feb 2025 | NT$104.6 million | +26.0% | -14.1% |
| Jan 2025 | NT$121.8 million | +9.9% | -2.4% |
| Dec 2024 | NT$124.8 million | +19.5% | +31.4% |
| Nov 2024 | NT$95 million | -2.3% | -10.1% |
| Oct 2024 | NT$105.7 million | +16.3% | -1.5% |
Jan–Oct 2026 cumulative: NT$1.25 billion (+8.0% YoY)
Other Biotech & Medical companies
Compare with peers: Vetnostrum vs PEC / Vetnostrum vs Lotus Pharm / Vetnostrum vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16